Pictet Asset Management SA Has $314,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Pictet Asset Management SA raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 18.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 4,146 shares of the company’s stock after acquiring an additional 642 shares during the period. Pictet Asset Management SA’s holdings in TransMedics Group were worth $314,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in TransMedics Group by 643.0% during the third quarter. Royal Bank of Canada now owns 1,122 shares of the company’s stock worth $46,000 after buying an additional 971 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in TransMedics Group by 125.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,603 shares of the company’s stock worth $109,000 after purchasing an additional 1,448 shares during the period. Captrust Financial Advisors boosted its position in shares of TransMedics Group by 738.8% during the first quarter. Captrust Financial Advisors now owns 5,788 shares of the company’s stock worth $156,000 after purchasing an additional 5,098 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of TransMedics Group by 161.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,998 shares of the company’s stock valued at $189,000 after buying an additional 3,705 shares during the period. Finally, Handelsbanken Fonder AB bought a new stake in shares of TransMedics Group in the 4th quarter valued at $204,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 5.2 %

Shares of TMDX stock opened at $64.27 on Wednesday. TransMedics Group, Inc. has a 52-week low of $38.86 and a 52-week high of $99.63. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -112.75 and a beta of 1.46. The firm’s 50-day moving average is $79.33 and its 200-day moving average is $76.43. The company has a debt-to-equity ratio of 3.48, a quick ratio of 19.74 and a current ratio of 20.70.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.12. TransMedics Group had a negative return on equity of 9.98% and a negative net margin of 11.77%. The business had revenue of $42.46 million for the quarter, compared to analysts’ expectations of $42.42 million. During the same quarter in the prior year, the business earned ($0.41) EPS. The firm’s revenue for the quarter was up 136.9% on a year-over-year basis. Sell-side analysts predict that TransMedics Group, Inc. will post -0.51 EPS for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $71.64, for a total transaction of $537,300.00. Following the completion of the sale, the chief executive officer now directly owns 551,691 shares in the company, valued at $39,523,143.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Waleed H. Hassanein sold 7,500 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $71.64, for a total transaction of $537,300.00. Following the transaction, the chief executive officer now owns 551,691 shares in the company, valued at $39,523,143.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Tamer I. Khayal sold 5,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, July 18th. The stock was sold at an average price of $95.37, for a total value of $476,850.00. Following the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,370,943.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,474 shares of company stock worth $2,598,734. Insiders own 6.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TMDX shares. Oppenheimer lifted their price objective on TransMedics Group from $90.00 to $92.00 in a report on Friday, August 4th. TD Cowen lifted their target price on TransMedics Group from $95.00 to $110.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. TheStreet raised TransMedics Group from a “d+” rating to a “c-” rating in a research report on Friday, August 4th. Robert W. Baird initiated coverage on shares of TransMedics Group in a report on Wednesday, July 19th. They issued an “outperform” rating on the stock. Finally, William Blair restated an “outperform” rating on shares of TransMedics Group in a report on Wednesday, July 19th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.